Page 87 - Read Online

Farrell et al. Hepatoma Res 2020;6:18 I http://dx.doi.org/10.20517/2394-5079.2019.019 Page 11 of 13

management becomes a greater focus of therapy, the ongoing risk of HCC in individuals with NAFLD who
have subsequently lost weight or undergone therapy will need to be evaluated.

CONCLUSION
NAFLD is an important cause of liver disease worldwide and is associated with an increased risk of
developing HCC, particularly in the presence of liver cirrhosis. While the absolute risk appears to be low,
prevalence of NAFLD-related HCC is increasing in parallel with the prevalence of NAFLD worldwide,
particularly in the West. The future global burden of NAFLD-related HCC represents a major public health
threat and further research to identify cost-effective prevention and treatment strategies are urgently
required.

DECLARATIONS
Authors’ contributions
Performed the literature review and generated the manuscript: Farrell A
Assisted in developing the outline for the manuscript: Howell J
Responsible for review of the manuscript: Ryan M, Howell J

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic
assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
2. Kim D, Touros A, Kim WR. Nonalcoholic fatty liver disease and metabolic syndrome. Clin Liver Dis 2018;22:133-40.
3. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, et al. Modeling NAFLD disease burden in China, France, Germany, Italy,
Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018;69:896-904.
4. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care 2004;27:2444-9.
5. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018;20:12.
6. Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, et al. Global trends and predictions in hepatocellular carcinoma mortality. J
Hepatol 2017;67:302-9.
7. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, et al. Global patterns of hepatocellular carcinoma management from diagnosis
to death: the BRIDGE Study. Liver Int 2015;35:2155-66.
8. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, et al. Association of nonalcoholic fatty liver disease (NAFLD) with
hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62:1723-30.
9. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association